Last reviewed · How we verify
Sequence B ABSK-011 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Sequence B ABSK-011 (Sequence B ABSK-011) — Abbisko Therapeutics Co, Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Sequence B ABSK-011 TARGET | Sequence B ABSK-011 | Abbisko Therapeutics Co, Ltd | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Sequence B ABSK-011 CI watch — RSS
- Sequence B ABSK-011 CI watch — Atom
- Sequence B ABSK-011 CI watch — JSON
- Sequence B ABSK-011 alone — RSS
Cite this brief
Drug Landscape (2026). Sequence B ABSK-011 — Competitive Intelligence Brief. https://druglandscape.com/ci/sequence-b-absk-011. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab